Reference

Age/sex

Type of ASP/treatment phase

Type of pancreatitis

Complications/ Surgery

Time from last dose of ASP and

pancreatitis

Octreotide dose/duration

Octreotide side effects

Re-exposure

Outcome

Wu et al. [5]

8 y/M

L-asp/

Induction

NR

Diabetes/No

Median 5.2 d

(range 2-14 d)

7.2 µg/kg/d civ for 6 d

No

No

Recovery

12 y/F

L-asp/

Induction

NR

Diabetes/No

7.2 µg/kg/d civ for 7 d

No

No

Recovery

13 y/F

L-asp/

Induction

NR

No/No

7.2 µg/kg/d civ for 4 d

No

No

Recovery

3 y/F

L-asp/

Induction

NR

No/No

7.2 µg/kg/d civ for 4 d

No

No

Recovery

Cheung et al.

[17]

8 y/F

L-asp/

Induction

Edematous

No/No

5 d

5.1-8.7 µg/kg/d iv tid for

44 d

NR

Yes, with

Erwinia-asp

Recovery

Koker et al.

[18]

15 y/F

L-asp/

Induction

Edematous

Hyperglycemia/No

1 d

2 μg/kg/h for 5 d

No

Yes, with

PEG-asp

Recovery

2 y/M

L-asp/

Induction

Edematous

No/No

3 d

2 μg/kg/h/NR

No

Yes, with

PEG-asp

Recovery

Garrington et al. [19]

5 y/F

L-asp/

Induction

Necrotizing

Pleural effusion, ascites,

pseudocyst/No

6 d

5 µg/kg/d iv bid for 7 d

No

No

Recovery

Top et al. [20]

15 y/F

L-asp/

Induction

Necrotizing

Sepsis, PFC pseudocyst,

diabetes^*/Yes

NR

NR/NR

NR

No

Recovery

Hatzipantelis et al. [21]

6.5 y/F

L-asp/

Induction

Necrotizing

No/No

5 d

3.6 μg/kg/d civ for 8 d

Seizures

NR

Recovery

Acer et al.

[22]

9 y/M

L-asp/NR

Necrotizing

Ascites, PFC, necrosis of transverse colon/Yes

NR

NR/NR

NR

NR

Recovery

Plotka et al.

[23]

13 y/M

PEG-asp/Reinduction

Necrotizing

Pleural effusion, ascites,

pseudocyst, hyperglycemia/ No

13 d

NR/NR

NR

No

Recovery

Our case

3 y/M

PEG-asp/Induction

Necrotizing

Pleural effusion, ascites,

PFC, pseudocyst, hyperglycemia/No

10 d

1 µg/kg/h for 18 d

No

No

Recovery